Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (44)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Keeling, K. M.
Right arrow Articles by Bedwell, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keeling, K. M.
Right arrow Articles by Bedwell, D. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, 2001, Vol. 10, No. 3 291-299
© 2001 Oxford University Press

Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of {alpha}-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation

Kim M. Keeling1, Doug A. Brooks3, John J. Hopwood3, Peining Li1, Jerry N. Thompson1 and David M. Bedwell1,2,+

Departments of 1Human Genetics and 2Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA and 3Lysosomal Diseases Research Unit, Department of Chemical Pathology, Women’s and Children’s Hospital, North Adelaide, South Australia, Australia

Hurler syndrome is the most severe form of a lysosomal storage disease caused by loss of the enzyme {alpha}-L-iduronidase (encoded by the IDUA gene), which participates in the degradation of glycosaminoglycans (GAGs) within the lysosome. In some populations, premature stop mutations represent roughly two-thirds of the mutations that cause Hurler syndrome. In this study we investigated whether the aminoglycoside gentamicin can suppress stop mutations within the IDUA gene. We found that a Hurler syndrome fibroblast cell line heterozygous for the IDUA stop mutations Q70X and W402X showed a significant increase in {alpha}-L-iduronidase activity when cultured in the presence of gentamicin, resulting in the restoration of 2.8% of normal {alpha}-L-iduronidase activity. Determination of {alpha}-L-iduronidase protein levels by an immunoquantification assay indicated that gentamicin treatment produced a similar increase in {alpha}-L-iduronidase protein in Hurler cells. Both the {alpha}-L-iduronidase activity and protein level resulting from this treatment have previously been correlated with mild Hurler phenotypes. Although Hurler fibroblasts contain a much higher level of GAGs than normal, we found that gentamicin treatment reduced GAG accumulation in Hurler cells to a normal level. We also found that a reduced GAG level could be sustained for at least 2 days after gentamicin treatment was discontinued. The reduction in the GAG level was also reflected in a marked reduction in lysosomal vacuolation. Taken together, these results suggest that the suppression of premature stop mutations may provide an effective treatment for Hurler syndrome patients with premature stop mutations in the IDUA gene.

+ To whom correspondence should be addressed at: Department of Microbiology, BBRB 432/Box 8, 1530 Third Avenue South, The University of Alabama at Birmingham, Birmingham, AL 35294-2170, USA. Tel: +1 205 934 6593; Fax: +1 205 975 5482; Email: dbedwell@uab.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JEMHome page
L. Du, R. Damoiseaux, S. Nahas, K. Gao, H. Hu, J. M. Pollard, J. Goldstine, M. E. Jung, S. M. Henning, C. Bertoni, et al.
Nonaminoglycoside compounds induce readthrough of nonsense mutations
J. Exp. Med., September 28, 2009; 206(10): 2285 - 2297.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. R. Heier and C. J. DiDonato
Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo
Hum. Mol. Genet., April 1, 2009; 18(7): 1310 - 1322.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Du, K. M. Keeling, L. Fan, X. Liu, and D. M. Bedwell
Poly-L-aspartic Acid Enhances and Prolongs Gentamicin-mediated Suppression of the CFTR-G542X Mutation in a Cystic Fibrosis Mouse Model
J. Biol. Chem., March 13, 2009; 284(11): 6885 - 6892.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Moosajee, K. Gregory-Evans, C. D. Ellis, M. C. Seabra, and C. Y. Gregory-Evans
Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease
Hum. Mol. Genet., December 15, 2008; 17(24): 3987 - 4000.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
R. Azimov, N. Abuladze, P. Sassani, D. Newman, L. Kao, W. Liu, N. Orozco, P. Ruchala, A. Pushkin, and I. Kurtz
G418-mediated ribosomal read-through of a nonsense mutation causing autosomal recessive proximal renal tubular acidosis
Am J Physiol Renal Physiol, September 1, 2008; 295(3): F633 - F641.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
S. M. Rowe, K. Varga, A. Rab, Z. Bebok, K. Byram, Y. Li, E. J. Sorscher, and J. P. Clancy
Restoration of W1282X CFTR Activity by Enhanced Expression
Am. J. Respir. Cell Mol. Biol., September 1, 2007; 37(3): 347 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
J. P. Clancy, S. M. Rowe, Z. Bebok, M. L. Aitken, R. Gibson, P. Zeitlin, P. Berclaz, R. Moss, M. R. Knowles, R. A. Oster, et al.
No Detectable Improvements in Cystic Fibrosis Transmembrane Conductance Regulator by Nasal Aminoglycosides in Patients with Cystic Fibrosis with Stop Mutations
Am. J. Respir. Cell Mol. Biol., July 1, 2007; 37(1): 57 - 66.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. E. Handy, G. Hang, J. Scolaro, N. Metes, N. Razaq, Y. Yang, and J. Loscalzo
Aminoglycosides Decrease Glutathione Peroxidase-1 Activity by Interfering with Selenocysteine Incorporation
J. Biol. Chem., February 10, 2006; 281(6): 3382 - 3388.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. D. James, S. Raut, G. E. Rivard, M.-C. Poon, M. Warner, S. McKenna, J. Leggo, and D. Lillicrap
Aminoglycoside suppression of nonsense mutations in severe hemophilia
Blood, November 1, 2005; 106(9): 3043 - 3048.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. M. Rowe, S. Miller, and E. J. Sorscher
Cystic Fibrosis
N. Engl. J. Med., May 12, 2005; 352(19): 1992 - 2001.
[Full Text] [PDF]

Home page
 Hum Mol GenetHome page
E. C. Wolstencroft, V. Mattis, A. A. Bajer, P. J. Young, and C. L. Lorson
A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels
Hum. Mol. Genet., May 1, 2005; 14(9): 1199 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
L S Correa-Cerro, C A Wassif, J S Waye, P A Krakowiak, D Cozma, N R Dobson, S W Levin, G Anadiotis, R D Steiner, M Krajewska-Walasek, et al.
DHCR7 nonsense mutations and characterisation of mRNA nonsense mediated decay in Smith-Lemli-Opitz syndrome
J. Med. Genet., April 1, 2005; 42(4): 350 - 357.
[Full Text] [PDF]

Home page
 BloodHome page
D. E. Sabatino, E. Armstrong, S. Edmonson, Y.-L. Liu, M. Pleimes, J. Schuettrumpf, J. Fitzgerald, R. W. Herzog, V. R. Arruda, and K. A. High
Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene
Blood, November 1, 2004; 104(9): 2767 - 2774.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
D. M. Janzen and A. P. Geballe
The effect of eukaryotic release factor depletion on translation termination in human cell lines
Nucleic Acids Res., August 23, 2004; 32(15): 4491 - 4502.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
K. Sangkuhl, A. Schulz, H. Rompler, J. Yun, J. Wess, and T. Schoneberg
Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo
Hum. Mol. Genet., May 1, 2004; 13(9): 893 - 903.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
M. Arakawa, M. Shiozuka, Y. Nakayama, T. Hara, M. Hamada, S.'i. Kondo, D. Ikeda, Y. Takahashi, R. Sawa, Y. Nonomura, et al.
Negamycin Restores Dystrophin Expression in Skeletal and Cardiac Muscles of mdx Mice
J. Biochem., November 1, 2003; 134(5): 751 - 758.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Wilschanski, Y. Yahav, Y. Yaacov, H. Blau, L. Bentur, J. Rivlin, M. Aviram, T. Bdolah-Abram, Z. Bebok, L. Shushi, et al.
Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis and CFTR Stop Mutations
N. Engl. J. Med., October 9, 2003; 349(15): 1433 - 1441.
[Abstract] [Full Text] [PDF]

Home page
 RNAHome page
J. CARNES, M. JACOBSON, L. LEINWAND, and M. YARUS
Stop codon suppression via inhibition of eRF1 expression
RNA, June 1, 2003; 9(6): 648 - 653.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
C Grayson, J P Chapple, K R Willison, A R Webster, A J Hardcastle, and M E Cheetham
In vitro analysis of aminoglycoside therapy for the Arg120stop nonsense mutation in RP2 patients
J. Med. Genet., January 1, 2002; 39(1): 62 - 67.
[Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
D.M. JANZEN and A.P. GEBALLE
Modulation of Translation Termination Mechanisms by cis- and trans-Acting Factors
Cold Spring Harb Symp Quant Biol, January 1, 2001; 66(0): 459 - 468.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.